SIGLEC1在疑似系统性红斑狼疮诊断中的评估
在232例疑似系统性红斑狼疮(SLE)患者中评估SIGLEC1的诊断准确性,SLE确诊76例(32.8%)。SIGLEC1灵敏度98.7%、特异度82.1%、阴性预测值99.2%、阳性预测值72.8%,其AUC(0.95)显著高于ANA、C3和C4,但与抗dsDNA抗体无显著差异。作者认为SIGLEC1阴性结果有助于排除SLE。
要点
- SIGLEC1诊断SLE的灵敏度为98.7%、特异度为82.1%、阴性预测值为99.2%。
- SIGLEC1的AUC(0.95)显著高于ANA(0.88)、C3(0.83)和C4(0.83)。
- SIGLEC1与抗dsDNA抗体AUC(0.90)相比无显著差异(P=0.163)。
核心结论
- IFN-I通路激活几乎可在所有新诊断SLE患者中检测到,SIGLEC1阴性结果对排除疑似SLE有较强价值。
研究设计与样本
- 研究纳入2015年10月至2020年9月转诊至本机构的232例疑似SLE患者,采用流式细胞术分析SIGLEC1。
- SLE确诊依据2019年EULAR/ACR分类标准,232例中确诊76例(32.8%)。
主要发现
- 确诊SLE患者的SIGLEC1值显著高于非SLE患者(P<0.0001)。
- SIGLEC1的灵敏度为98.7%、特异度为82.1%、阴性预测值为99.2%、阳性预测值为72.8%。
- 按最高报告的SLE患病率调整后,SIGLEC1的阴性预测值>99.9%、阳性预测值为0.1%。
- ROC分析及DeLong检验显示,SIGLEC1的AUC(0.95)显著高于ANA(0.88,P=0.031)、C3(0.83,P=0.001)和C4(0.83,P=0.002)。
- SIGLEC1的AUC(0.95)与抗dsDNA抗体(0.90)相比无显著差异(P=0.163)。
关键数值与推荐
- SIGLEC1诊断SLE的灵敏度98.7%、特异度82.1%、阴性预测值99.2%、阳性预测值72.8%。
- 按最高报告患病率调整后,SIGLEC1的阴性预测值>99.9%、阳性预测值0.1%。
- SIGLEC1的AUC=0.95,ANA的AUC=0.88(P=0.031),C3的AUC=0.83(P=0.001),C4的AUC=0.83(P=0.002),抗dsDNA抗体的AUC=0.90(P=0.163)。
临床怎么用
- 原文结论认为,在疑似SLE病例中SIGLEC1阴性结果对排除SLE有较强价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate and compare the diagnostic accuracy of SIGLEC1, a surrogate marker of type I IFN, with established biomarkers in an inception cohort of systemic lupus erythematosus (SLE). METHODS: SIGLEC1 was analysed by flow cytometry in 232 patients referred to our institution with suspected SLE between October 2015 and September 2020. RESULTS: SLE was confirmed in 76 of 232 patients (32.8 %) according to the 2019 EULAR/ACR classification criteria and their SIGLEC1 values were significantly higher compared with patients without SLE (P <0.0001). A sensitivity of 98.7 %, a specificity of 82.1 %, a negative predictive value (NPV) of 99.2 % and a positive predictive value (PPV) of 72.8 % were calculated for SIGLEC1. Adjusted to the highest reported prevalence of SLE, the NPV and PPV were >99.9 % and 0.1 %, respectively. Using receiver operating characteristic (ROC) analysis and DeLong testing, the area under the curve (AUC) for SIGLEC1 (AUC = 0.95) was significantly higher than for ANA (AUC = 0.88, P = 0.031), C3 (AUC = 0.83, P = 0.001) and C4 (AUC = 0.83, P = 0.002) but not for anti-dsDNA antibodies (AUC = 0.90, P = 0.163). CONCLUSION: IFN-I pathway activation is detectable in almost all newly diagnosed SLE patients. Thus, a negative test result for SIGLEC1 is powerful to exclude SLE in suspected cases.
引用
- Zorn-Pauly L, von Stuckrad ASL, Klotsche J, et al. Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus. Rheumatology (Oxford). 2022. PMID: 34849605. doi:10.1093/rheumatology/keab875
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。